Sartorius (SARTF) Stock Price, News & Analysis

Company Overview

Sartorius AG, trading in the U.S. over the counter under the symbol SARTF, is a Germany-based provider of laboratory and bioprocessing equipment for the pharmaceutical, biotechnology and research industries. The company is organized into two core divisions: Bioprocess Solutions, which focuses on single-use consumables, filtration technologies and upstream and downstream processing systems; and Lab Products & Services, which supplies laboratory instruments, consumables and services, including balances, pipettes, cell counting systems and water purification units.

The Bioprocess Solutions segment serves customers engaged in the development and manufacture of biopharmaceuticals, vaccines and advanced therapies. Its product range includes single-use bioreactors, tangential flow filtration systems, media and buffer preparation tools and process analytics. In the Lab Products & Services segment, Sartorius offers high-precision laboratory balances, pipetting devices, lab filtration products and software-driven services aimed at improving workflow efficiency and data integrity in quality control and R&D laboratories.

Founded in 1870 in Göttingen, Germany, Sartorius has expanded its global footprint with production and service sites across Europe, North America and Asia. The company supports research institutions, contract development and manufacturing organizations (CDMOs) and major pharmaceutical manufacturers in over 100 countries. Its executive board is chaired by Dr. Joachim Kreuzburg, under whose leadership Sartorius has pursued both organic growth and strategic acquisitions to strengthen its technology portfolio and international presence.

Key Stats

• Today's Range: $212.35 to $212.35
• 50-Day Range: $212.35 to $226.33
• 52-Week Range: $181.58 to $226.33
• Volume: N/A
• Average Volume: 75 shs
• Market Capitalization: $7.27 billion
• P/E Ratio: 98.77
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Sartorius Stock Analysis - MarketRank™

Sartorius scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

Sartorius has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sartorius is 98.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sartorius is 98.77, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.47.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Sartorius has been sold short.

Short Interest Ratio / Days to Cover

Sartorius has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sartorius has recently increased by 407.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sartorius does not currently pay a dividend.

Dividend Growth

Sartorius does not have a long track record of dividend growth.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.01

News Sentiment

Sartorius has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Sartorius this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sartorius insiders have not sold or bought any company stock.

Percentage Held by Institutions

Sartorius has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 10/16/2025
• Today: 5/15/2026
• Next Earnings (Estimated): 7/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SARTF
• Previous Symbol: NASDAQ:SARTF
• CIK: N/A
• Web: www.sartorius.com
• Phone: 495513080
• Fax: 49-55-1308-3289
• Employees: 13,528
• Year Founded: 1870

Profitability

• EPS (Trailing Twelve Months): $2.15
• Trailing P/E Ratio: 98.77
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $90.90 million
• Net Margins: 3.82%
• Pretax Margin: 8.16%
• Return on Equity: 8.19%
• Return on Assets: 3.15%

Debt

• Debt-to-Equity Ratio: 0.89
• Current Ratio: 0.95
• Quick Ratio: 0.49

Sales & Book Value

• Annual Sales: $3.66 billion
• Price / Sales: 1.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,230,000
• Free Float: N/A
• Market Cap: $7.27 billion
• Optionable: Not Optionable
• Beta: 0.98